526 – Long-Acting Cabotegravir & Rilpivirine: Real-World Outcomes at 3 Years (ANRS CO3 AquiVIH-NA Cohort)
Background Long term safety and virologic outcomes, therapeutic drug monitoring and patient reported outcomes on health-related quality of life and treatment satisfaction of CAB-RPV LA in routine clinical care have rarely been described Methods In the ANRS CO3-AQUIVIH-NA observational cohort in South-Western France, all adults living with HIV who received their first CAB + RPV LA…